New schizophrenia drug shows promise in early trial

NCT ID NCT03055338

Completed Symptom relief Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen May 02, 2026 · Last updated May 15, 2026 · Updated 4 times

Summary

This study tested a new drug called MK-8189 (elpipodect) in 224 adults experiencing an acute episode of schizophrenia. Participants received either MK-8189, a placebo, or an active control drug (risperidone) for 4 weeks. The main goal was to see if MK-8189 reduces schizophrenia symptoms better than placebo, as measured by a standard symptom scale.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Alexian Center for Psychiatric Research ( Site 0015)

Hoffman Estates, Illinois, 60169, United States
Altea Research Institute ( Site 0017)

Las Vegas, Nevada, 89102, United States
Artemis Institute for Clinical Research ( Site 0027)

San Diego, California, 92103, United States
Aspire Health Partners ( Site 0016)

Orlando, Florida, 32810, United States
Atlanta Center For Medical Research ( Site 0056)

Atlanta, Georgia, 30331, United States
Behavioral Research Specialists, LLC ( Site 0006)

Glendale, California, 91206, United States
CBH Health, LLC ( Site 0022)

Gaithersburg, Maryland, 20877, United States
CITRIALS ( Site 0013)

Bellflower, California, 90706, United States
CNRI - Los Angeles, LLC ( Site 0026)

Pico Rivera, California, 90660, United States
Clinical Research Centers of America, LLC ( Site 0038)

Oakland Park, Florida, 33334, United States
Collaborative Neuroscience Network, LLC ( Site 0046)

Torrance, California, 90502, United States
Collaborative Neuroscience Network, LLC ( Site 0057)

Garden Grove, California, 92845, United States
Comprehensive Clinical Development ( Site 0049)

Cerritos, California, 90703, United States
InSite Clinical Research ( Site 0033)

DeSoto, Texas, 75115, United States
Lake Charles Clinical Trials, LLC ( Site 0040)

Lake Charles, Louisiana, 70629, United States
Larkin Community Hospital Behavioral Health Services ( Site 0020)

Hollywood, Florida, 33021, United States
Midwest Clinical Research Unit ( Site 0041)

Dayton, Ohio, 45417, United States
NRC Research Institute ( Site 0043)

Orange, California, 92868, United States
Pillar Clinical Research, LLC ( Site 0004)

Richardson, Texas, 75080, United States
Precise Research Centers ( Site 0018)

Flowood, Mississippi, 39232, United States
Psych Care Consultants Research ( Site 0025)

St Louis, Missouri, 63128, United States
Radiant Research - Atlanta ( Site 0008)

Atlanta, Georgia, 30328, United States
Radiant Research -CliniLabs ( Site 0037)

New York, New York, 10019, United States
Schuster Medical Research Institute ( Site 0032)

Sherman Oaks, California, 91403, United States
St. Louis Clinical Trials, LLC ( Site 0012)

St Louis, Missouri, 63141, United States
Synergy East ( Site 0003)

Lemon Grove, California, 91945, United States
Woodland International Research Group, LLC ( Site 0001)

Little Rock, Arkansas, 72211, United States
Woodland Research Northwest, LLC ( Site 0014)

Rogers, Arkansas, 72758, United States

Conditions

Explore the condition pages connected to this study.

SCHIZOPHRENIA, ACUTE EPISODE